Beat on FY24 results but guidance is disappointing.

Solid 24 results and decent 25 Guidance.

Novo Nordisk

Beat on 24 numbers - Somewhat weak guidance could prompt consensus downgrade.

Beat on FY results but weak guidance for 25 and a cost cutting plan

FY25 results better. 25 Guidance is soft but trend is positive.